Idiosyncratic drug-induced agranulocytosis: Possible mechanisms and management
| Autor: | Jan Palmblad, Daniel Tesfa, Marianne Keisu |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Drug
medicine.medical_specialty Neutropenia media_common.quotation_subject Patient characteristics Host factors Epigenesis Genetic Lymphopenia medicine Humans Drug Interactions Genetic Predisposition to Disease Intensive care medicine Adverse effect media_common Western hemisphere Mechanism (biology) business.industry Immune regulation Hematology Drug-induced agranulocytosis Immunology Intercellular Signaling Peptides and Proteins Reactive Oxygen Species business Agranulocytosis |
| Zdroj: | American Journal of Hematology. 84:428-434 |
| ISSN: | 1096-8652 0361-8609 |
| Popis: | The incidence of drug-induced neutropenia has not changed in the western hemisphere over the last 30 years. Yet, the drug panorama has changed considerably. This implies that host factors may play an intriguing role for this idiosyncratic reaction. The knowledge as to mechanisms for the reaction has advanced with emerging understanding of neutropoiesis and immune regulation. Nonetheless, it is still remarkably difficult to pinpoint why and how a drug causes this unexpected, severe adverse event in a patient. Patient characteristics, e.g. genetics, appear to be keys for better understanding, predictions and prevention. Am. J. Hematol. 2009. (c) 2009 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text